Evolus (NASDAQ:EOLS) initiated with an Outperform rating and $20 (75% upside) price target at JMP Securities.Initiated with Buy rating and $24 price target at SunTrust. Initiated with Overweight rating and $25 price target at Cantor Fitzgerald. Initiated with Buy rating and $21 price target at Mizuho Securities.
MacroGenics (NASDAQ:MGNX) initiated with Buy rating and $38 (31% upside) price target at H.C. Wainwright.
Revance Therapeutics (NASDAQ:RVNC) initiated with Buy rating and $60 (92% upside) price target at Goldman Sachs.
Bluebird bio (NASDAQ:BLUE) initiated with Outperform rating at William Blair.
Valeant Pharmaceuticals (NYSE:VRX) upgraded to Buy at Deutsche Bank. Shares up 5% premarket.
GTx (NASDAQ:GTXI) price target raised to $45 (168% upside) at Stifel citing bullish prospects for enobosarm. Shares up 25% premarket.
Vertex Pharmaceuticals (NASDAQ:VRTX) price target raised to $200 (18% upside) at Maxim Group following Symdeko approval in U.S.
Omeros (NASDAQ:OMER) downgraded to Hold at Needham citing Omidria uncertainty.
LifePoint Health (NASDAQ:LPNT) downgraded to Market Perform at Leerink Partners.
AMAG Pharmaceuticals (NASDAQ:AMAG) downgraded to Hold at Jefferies.
Subscribe for full text news in your inbox